SLXN

SEC filing SLXN Announces 1-for-10 Reverse Share Split to Comply with Nasdaq Requirements, Enhance Market Position

7d ago

News US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings

14d ago

SEC filing SLXN Initiates GMP Manufacturing of SIL204 with Catalent, Secures Helsinki Ethics Approval for Phase 2/3 KRAS‑Driven Pancreatic Cancer Trial

20d ago

SEC filing SLXN Amends Memorandum to Boost Authorized Shares to 59M, Expand 2024 Plan Evergreen to 10% Fully Diluted, Approve 1-for-10 Reverse Split

27d ago

SEC filing SLXN Announces Phase 2/3 CTA Submission to Germany for SIL204 in KRAS Pancreatic Cancer, Dual-Targeting Trial Planned Q2 2026

35d ago

SEC filing SLXN Removes Ilan Levin Director Effective Immediately via Unanimous Board Vote

68d ago

SEC filing SLXN Receives Israeli MoH Approval for Phase 2/3 SIL204 Trial in Pancreatic Cancer, KRAS-Targeted RNAi Therapy, Preclinical Anti-Tumor Activity Demonstrated, Plans 2026 Initiation, EU Submissions Planned

70d ago

News Abbott eyes $20B bond sale to fund purchase of Exact Sciences - report

99d ago

News Abbott Kicks Off Bond Sale for Exact Sciences Deal

99d ago

News Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal

99d ago

News VCI Global announces strategic transformation into AI-native platform

125d ago

News Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

155d ago